We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Optibrium Releases Powerful Metabolism Prediction Capability in Next Generation StarDrop Software

An assortment of different pills.
Credit: freestocks / Unsplash.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Optibrium, a leading developer of software and AI solutions for drug discovery, today launched the latest version of its drug discovery platform, StarDrop 7.5, introducing a powerful module for drug metabolism prediction. The culmination of six years’ research and development, the new StarDrop Metabolism module uniquely combines quantum mechanics and machine learning to better predict the metabolic fate of drug candidates. The module covers a broad range of drug-metabolising enzymes with greater precision than comparable methods.


Late-stage drug failures can often be attributed to issues relating to drug metabolism, such as poor metabolic stability resulting in low bioavailability of the active compound, unforeseen drug–drug interactions, or the formation of reactive or toxic metabolites. Early-stage predictive modelling of drug metabolism is therefore critical to overcome these challenges and save time, costs, and resources in the long-term.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Optibrium’s new StarDrop Metabolism module covers 80% of Phase I and 60% of Phase II human metabolism, building on the Company’s 25 years of experience modelling metabolism by cytochrome P450s. The module spans a range of key drug-metabolising enzymes: cytochrome P450s (CYPs), aldehyde oxidases (AOXs), flavin-containing monooxygenases (FMOs), uridine diphosphate glucuronosyltransferases (UGTs), and sulfotransferases (SULTs). The module includes regioselectivity models for these enzymes, enabling users to predict which atomic sites are most likely to be metabolised and the resulting metabolites. Combining these with models that predict which enzyme families and isoforms will metabolise a compound allows users to identify, with precision, which metabolites are most likely to be observed in vivo, design compounds with improved metabolic stability and reduce the risk of drug-drug interactions. Furthermore, models for CYP metabolism in rat, mouse, and dog help researchers select the best species for preclinical studies.


The models have been rigorously validated, as exemplified through recent peer-reviewed publications1-6, including ‘Predicting Regioselectivity of AO, CYP, FMO and UGT Metabolism Using Quantum Mechanical Simulations and Machine Learning’ in the Journal of Medicinal Chemistry and ‘Predicting Regioselectivity of Cytosolic SULT Metabolism for Drugs’ in the Journal of Chemical Information and Modeling. Balanced accuracy values of up to 98% were achieved across this research.